-
-
-
-
-
-
-
BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $120 at Baird; Sees at Least a 2-Year Valrox Delay Following CRL
-
-
-
-
-
-
-
BioMarin to Attend Upcoming Investor Conferences
-
-
-
-
-
-
-
Notable Analyst Rating Changes 3/8: (BMRN) (SHOP) (PNRA) Upgraded; (AN) (SAM) (EPE) Downgraded
-
-
-
-
-
-
-
Baird Reiterates Bullish View on Sarepta (SRPT) Following Eteplirsen NDA Acceptance
-
-
-
-
-
-
-
BioMarin to Present at Upcoming Investor Conferences
-
-
-
-
-
-
-
Notable Analyst Rating Changes 02/18: (TRGL) (SPWRA) (BRCD) (ZMH) Upgraded; (ACOR) (VCLK) (BMRN) (PEP) Downgraded
-
-
-
-
-
-
-
Baird Reiterates Outperform on BioMarin Pharma (BMRN); Ups PT to $46
-
28,071 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

